



26 June 2025

Completion of ALS' Share Purchase Plan

ALS Limited (ASX: ALQ) (ALS) confirms the completion of its non-underwritten share purchase plan (SPP), initially announced to the market on Tuesday, 27 May 2025.

On Friday 27 June 2025, ALS will issue 1,351,557 new fully paid ordinary shares in ALS at \$16.51 per share, raising approximately \$22.5 million, with applications by participating shareholders accepted in full. The new shares are expected to commence trading on ASX on Monday, 30 June 2025 and will be entitled to the FY25 final dividend.

Holding statements are expected to be dispatched on 30 June 2025.

Authorised for release by the Board of Directors.

For further information please contact:

Michael Williams

Group Treasurer, Investor Relations &
Business Integration Director

michael.williams@alsglobal.com

M: + 61 409 001 308

Investor Relations

investor@alsglobal.com

ALS Limited

Media enquiries

media@alsglobal.com

ALS Limited

About ALS Limited (ASX: ALQ)

ALS is a global leader in testing, providing comprehensive testing solutions to clients in a wide range of industries around the world. Using state-of-the-art technologies and innovative methodologies, our dedicated international teams deliver the highest-quality testing services and personalised solutions supported by local expertise. We help our clients leverage the power of data-driven insights for a safer and healthier world.



NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES

This announcement may not be distributed or released in the United States. New Shares have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the “**U.S. Securities Act**”), or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold, directly or indirectly, in the United States or to any person acting for the account or benefit of a person in the United States, unless they have been registered under the U.S. Securities Act (which ALS has no obligation to do or procure) or are offered or sold in a transaction exempt from, or not subject to, the registration requirements of the U.S. Securities Act and any other applicable U.S. state securities laws. ALS does not intend to conduct a public offering of securities in the United States.

Forward-looking statements

This announcement contains certain forward-looking statements. Words such as “continue”, “expect”, “forecast”, “anticipate”, “estimate”, “intend”, “believe”, “potential”, “likely”, “may”, “will”, “predict” or such similar phrases are intended to identify forward-looking statements. Investors should not place undue reliance on such forward-looking statements, especially in view of the current and challenging economic, market, climate, supply chain and other uncertainty and disruption, including the conflicts in the Ukraine and the Middle East. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that are beyond the control of ALS.

General

Nothing contained in this announcement constitutes financial product, legal, tax or other advice or recommendation. It does not take into account the investment objectives, financial situation or needs of any particular investor. You should make your own assessment and take independent professional advice in relation to the information and any action on the basis of the information.